Últimas noticias sobre Bio-Path Hldgs (NASDAQ:BPTH) Bolsa

Bio-Path Hldgs

Bio-Path Holdings

Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.

Bio-Path Holdings Inc

<h3>Gainers</h3>
<ul>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares moved upwards by 53.2% to $1.9 during Thursday's pre-market session. The company's market cap stands at $2.5 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares moved upwards by 22.1% to $0.12. The company's market cap stands at $11.1 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) stock moved upwards by 14.0% to $0.23. The market value of their outstanding shares is at $4.1 million. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) shares increased by 13.45% to $0.42. The company's market cap stands at $4.1 million. </li>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares rose 12.01% to $0.99. The company's market cap stands at $2.5 million. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) shares rose 10.69% to $8.9. The market value of their outstanding shares is at $11.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock decreased by 16.0% to $1.21 during Thursday's pre-market session. The company's market cap stands at $1.9 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) stock fell 14.79% to $4.15. The market value of their outstanding shares is at $9.4 million. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) shares decreased by 11.59% to $0.39. The market value of their outstanding shares is at $11.4 million. </li>
<li>ALT5 Sigma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTS#NASDAQ">ALTS</a>) stock declined by 11.3% to $1.58. The market value of their outstanding shares is at $21.3 million. </li>
<li>Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) stock decreased by 9.63% to $4.44. The company's market cap stands at $4.6 million. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) stock decreased by 9.08% to $17.23. The company's market cap stands at $3.7 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALTS

BPTH

Hims & Hers Health, Inc. Class A Common Stock

HIMS

KTTA

KZIA

NDRA

RDHL

SNGX

SYRA

TOVX

WINT

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) stock increased by 27.4% to $0.16 during Monday's after-market session. The company's market cap stands at $15.0 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) stock moved upwards by 18.82% to $2.02. The market value of their outstanding shares is at $4.7 million. </li>
<li>Holdco Nuvo Group DG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVO#NASDAQ">NUVO</a>) stock increased by 17.64% to $0.2. The market value of their outstanding shares is at $6.6 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock rose 8.62% to $0.64. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) stock increased by 8.56% to $0.76. The market value of their outstanding shares is at $46.9 million. </li>
<li>Qilian Intl Hldg Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGM#NASDAQ">BGM</a>) stock rose 7.88% to $7.25. The market value of their outstanding shares is at $52.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) shares declined by 13.8% to $0.27 during Monday's after-market session. The market value of their outstanding shares is at $22.4 million. </li>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock decreased by 13.46% to $0.16. The company's market cap stands at $1.0 million. </li>
<li>IO Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) stock fell 10.67% to $1.34. The company's market cap stands at $88.2 million. </li>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) stock decreased by 8.59% to $0.91. The market value of their outstanding shares is at $2.3 million. </li>
<li>FibroBiologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBLG#NASDAQ">FBLG</a>) stock fell 8.03% to $1.49. The market value of their outstanding shares is at $52.5 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares decreased by 7.05% to $0.52. The company's market cap stands at $7.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDRX

BJDX

FBLG

IOBT

NUVO

PASG

RNLX

TNFA

VTAK

12 Health Care Stocks Moving In Monday's After-Market Session

Bio-Path Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares closed slightly higher Wednesday after the company provided an update from its ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients and reported continued patient progress from its ongoing Phase 2 triple combination study of prexigebersen<a href="https://www.benzinga.com/pressreleases/24/08/g40481410/bio-path-holdings-reports-solid-tumor-patient-response-supporting-bp1001-as-compelling-potential-a"> in Acute Myeloid Leukemia.</a>
The Details: Bio-Path said the first patient treated with the higher dose in its Phase 1/1b study of BP1001-A has shown tumor regression and stable disease.&nbsp;
&#8220;These positive responses mark a significant milestone for Bio-Path as they suggest our DNAbilize platform technology has the potential to produce multiple drug candidates capable of target-specific protein inhibition for over-expressed, disease-causing gene products,&#8221; said Peter H. Nielsen, CEO of Bio-Path.
Read Next: <a href="https://www.benzinga.com/news/24/08/40474316/microchip-technology-stock-dips-after-cybersecurity-incident">Microchip Technology Stock Dips After Cybersecurity Incident</a>
What Else: Bio-Path reported its second-quarter <a href="https://www.benzinga.com/pressreleases/24/08/g40390303/bio-path-holdings-reports-second-quarter-2024-financial-results">financial results </a>last week and beat analyst expectations with GAAP losses of $1.16 per share. 
Research and development expenses decreased to $1.9 million primarily due to decreased manufacturing expenses and partially offset by an increase in expenses related to its clinical trial for BP1002 in lymphoma due to increased patient enrollment in 2024.
Bio-Path shares are moving lower in Wednesday&#8217;s after-hours session. 
BPTH Stock Prediction 2024: Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Bio-Path Holdings, an investor could make an assessment about a stock's long-term prospects using a moving average and trend line. 
If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Bio-Path, the 200-day moving average sits at $5.55, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, which is above the current price of $1.40. For more on charts and trend lines, <a href="https://pro.benzinga.com/">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
BPTH Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Bio-Path Holdings shares are down 6.7% after-hours at $1.40 at the time of publication Wednesday.
<ul>
<li>Read Also:<a href="https://www.benzinga.com/news/24/08/40473695/whats-going-on-with-nano-nuclear-energy-stock"> What&#8217;s Going On With Nano Nuclear Energy Stock?</a></li>
</ul>
Photo: Shutterstock

Biotech

News

Health Care

After-Hours Center

What Happened With Bio-Path Stock Today?

WIIM

Bio-Path Holding shares are trading lower. The company announced an update from it's ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients and reports continued patient progress from the ongoing Phase 2 triple combination study of prexigebersen in Acute Myeloid Leukemia.

Trading Ideas

Bio-Path Shares Halted On Circuit Breaker To The Downside, Stock Now Down -14.2%

General

Bio-Path Holdings shares are trading higher after the company  provided an update from its ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients and reported continued patient progress from the its ongoing Phase 2 triple combination study of prexigebersen in Acute Myeloid Leukemia.

Bio-Path Holdings Provides Update From Phase 1/1b Trial Of BP1001-A In Solid Tumor Patients; Says First Solid Tumor Patient Treated With Second, Higher Dose In Trial Experienced Tumor Reduction And Continued Stable Disease

Bio-Path Holdings shares are trading higher after the company reported better-than-expected Q2 EPS results.

Bio-Path Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) reported quarterly losses of $(1.16) per share which beat the analyst consensus estimate of $(1.54) by 24.68 percent. This is a 89.1 percent increase over losses of $(10.64) per share from the same period last year.

Earnings

Earnings Beats

Bio-Path Holdings Q2 2024 GAAP EPS $(1.16) Beats $(1.54) Estimate

Roth MKM analyst Philip Shen reiterates Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) with a Buy and maintains $20 price target.

Price Target

Reiteration

Analyst Ratings

Roth MKM Reiterates Buy on Bio-Path Hldgs, Maintains $20 Price Target

Peter H. Nielsen, President and Chief Executive Officer of Bio-Path, said,&nbsp;&quot;With the increased clinical data that we have generated, we are now able to develop the biomarkers needed to incorporate into our oncology studies. In addition, we have completed preparations for preclinical work to support advancing prexigebersen as a potential treatment for obesity. In tandem, we are designing development plans for first-in-human clinical studies in this expansive global market for weight loss.&quot;

Bio-Path Reports Meaningful Progress Across Key Clinical Trials In Multiple Cancer Indications

Bio-Path Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares are trading higher Friday after the company announced interim results from its Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the <a href="https://www.benzinga.com/pressreleases/24/06/g39329287/bio-path-holdings-presents-data-from-ongoing-phase-2-combination-study-of-prexigebersen-for-treatm">treatment of acute myeloid leukemia</a>.
The Details:
Bio-Path said the data presented showed prexigebersen continues to be well-tolerated and demonstrated efficacy results in two reporting cohorts including evaluable newly diagnosed AML patients and evaluable refractory/relapsed AML patients, both of which exceeded outcomes with frontline therapy.
&#8220;It was a pleasure to present these compelling data to an audience of European oncologists who treat AML patients and understand the continued great need for new therapeutic options,&#8221; said Peter Nielsen, CEO of Bio-Path.&nbsp;
&#8220;Given that our study is being conducted in the U.S., this encore presentation is an important step towards educating global oncology leaders on the benefits of prexigebersen and its potential to be another tool in their fight against AML.&#8221;
Related News: <a href="https://www.benzinga.com/news/24/06/39318261/whats-going-on-with-longeveron-stock">What&#8217;s Going On With Longeveron Stock?</a>
<h2 class="wp-block-heading">BPTH Stock Prediction 2024: </h2>
Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.
Shares of Bio-Path Holdings have an average 1-year price target of $40, representing an expected upside of 1900%.
Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. No analysts have bearish recommendations on Bio-Path, while 2 analysts have bullish ratings. The street high price target from Roth MKM is $40. 
BPTH Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Bio-Path shares are up 13.5% at $2.27 at the time of publication Friday.
Image: Shutterstock

Why Bio-Path Stock Is Climbing Today

ADBE: 16% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/39329925">Adobe shares are trading higher following better-than-expected Q2 earnings and strong guidance.</a>
BPTH: 46% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/39330417">Bio-Path Holdings shares are trading higher after the company announced interim results from its Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia.</a>
MOLN: 14% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/39330515">Molecular Partners shares are trading higher after the comapny announced preclinical proof-of-concept data from MP0621.</a>

ADBE

MOLN

Market-Moving News for June 14th

<h3>Gainers</h3>
<ul>
<li>Ainos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIMD#NASDAQ">AIMD</a>) stock rose 54.8% to $1.27 during Friday's pre-market session. The market value of their outstanding shares is at $8.2 million. </li>
<li>Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) shares moved upwards by 34.15% to $3.61. The company's market cap stands at $22.9 million. </li>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares increased by 20.99% to $2.42. The market value of their outstanding shares is at $4.4 million. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) stock moved upwards by 17.24% to $5.1. The market value of their outstanding shares is at $11.7 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares moved upwards by 12.84% to $1.23. The company's market cap stands at $3.6 million. </li>
<li>Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) stock increased by 12.6% to $6.7. The market value of their outstanding shares is at $222.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Opthea (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPT#NASDAQ">OPT</a>) stock decreased by 36.0% to $1.6 during Friday's pre-market session. The market value of their outstanding shares is at $132.5 million. </li>
<li>Gain Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) shares declined by 26.46% to $1.39. The market value of their outstanding shares is at $25.0 million. </li>
<li>Alzamend Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) stock fell 15.09% to $0.48. The company's market cap stands at $3.5 million. </li>
<li>JanOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAN#NASDAQ">JAN</a>) stock fell 13.74% to $2.08. The company's market cap stands at $24.2 million. </li>
<li>Rezolute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLT#NASDAQ">RZLT</a>) shares fell 13.18% to $4.48. The market value of their outstanding shares is at $179.8 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock fell 11.77% to $0.61. The market value of their outstanding shares is at $3.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEMD

AIMD

ALZN

GANX

LGVN

MBRX

RZLT

TNXP

12 Health Care Stocks Moving In Friday's Pre-Market Session

Bio-Path Holdings shares are trading higher after the company announced interim results from its Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia.

The company&nbsp;presented interim results from the Company&#39;s Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML) in a poster presentation at 2024 European Hematology Association (EHA) Congress, on June 14, 2024 in Madrid, Spain. 
&nbsp;
Jorge Cortes, M.D., Director of the Georgia Cancer Center, presented data showing prexigebersen continues to be well-tolerated and has now demonstrated compelling efficacy results in two reporting cohorts including evaluable newly diagnosed AML patients and evaluable refractory/relapsed AML patients, both of which exceeded outcomes with frontline therapy.

Bio-Path Holdings Reveals Interim Results From Phase 2 Study Of prexigebersen In Combination With decitabine And venetoclax For Treatment Of Acute Myeloid Leukemia

Bio-Path Holdings shares are trading lower after the company announced a $4 million private placement.

Bio-Path Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) ("Bio-Path" or the "Company"), a biotechnology company leveraging its proprietary DNAbilize&#xAE; liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,809,955 shares of its common stock (or common stock equivalents in lieu thereof), series A warrants to purchase up to 1,809,955 shares of common stock and short-term series B warrants to purchase up to 1,809,955 shares of common stock at a purchase price of $2.21 per share of common stock (or per common stock equivalent in lieu thereof) and accompanying warrants in a private placement priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants will have an exercise price of $2.00 per share and will be exercisable immediately upon issuance. The series A warrants will expire five years from the date of issuance and the short-term series B warrants will expire twenty-four months from the date of issuance. The closing of the offering is expected to occur on or about June 5, 2024, subject to the satisfaction of customary closing conditions. &nbsp;
H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.

Offerings

Bio-Path Holdings Announces $4M Private Placement Of 1,809,955 Shares Of Its Common Stock, Series A Warrants To Purchase Up To 1,809,955 Shares Of Common Stock And Short-Term Series B Warrants To Purchase Up To 1,809,955 Shares Of Common Stock At A Purchase Price Of $2.21

<h3>Gainers</h3>
<ul>
<li>Annexon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>) shares increased by 57.2% to $7.2 during Tuesday's pre-market session. The market value of their outstanding shares is at $665.3 million. </li>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) shares moved upwards by 36.08% to $0.48. The company's market cap stands at $11.8 million. </li>
<li>SunLink Health Systems (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SSY#AMEX">SSY</a>) stock moved upwards by 32.45% to $0.8. The market value of their outstanding shares is at $5.6 million. </li>
<li>Adlai Nortye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANL#NASDAQ">ANL</a>) stock moved upwards by 15.96% to $7.12. The market value of their outstanding shares is at $262.7 million. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) shares rose 15.74% to $1.47. The market value of their outstanding shares is at $3.9 million. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) stock increased by 15.41% to $3.07. The company's market cap stands at $18.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares declined by 24.1% to $2.45 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.0 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares declined by 9.3% to $0.49. The market value of their outstanding shares is at $4.2 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares decreased by 8.88% to $0.35. The market value of their outstanding shares is at $5.4 million. </li>
<li>MyMD Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYMD#NASDAQ">MYMD</a>) shares decreased by 8.17% to $1.8. The company's market cap stands at $4.1 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock decreased by 7.98% to $1.27. The market value of their outstanding shares is at $12.8 million. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) shares decreased by 7.84% to $0.8. The company's market cap stands at $17.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANNX

FRES

KDLY

MyMD Pharmaceuticals, Inc. - Common Stock

MYMD

MYNZ

NIVF

STSS

TCON

XCUR

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones falling more than 300 points on Monday.
The Dow traded down 0.81% to 38,371.77 while the NASDAQ climbed 0.04% to 16,741.41. The S&amp;P 500 also fell, dropping, 0.38% to 5,257.50.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/06/39133525/these-3-real-estate-stocks-delivering-high-dividend-yields-are-recommended-by-wall-stree">These 3 Real Estate Stocks Delivering High-Dividend Yields Are Recommended By Wall Street&#8217;s Most Accurate Analyst</a>s
Leading and Lagging Sectors Health care shares rose by 0.4% on Monday.
In trading on Monday, energy shares fell by 3.2%.
Top Headline
Science Applications International Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NYSE">SAIC</a>) reported a 9% revenue decline year over year in the fiscal first quarter of 2025 to $1.847 billion, marginally beating the analyst consensus estimate of $1.844 billion.
Adjusted EPS of $1.92 was in line with the analyst consensus estimate.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Bio-Path Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares shot up 42% to $2.9295 after the company announced the presentation of data from its ongoing Phase 2 combination study of prexigebersen for the treatment of acute myeloid leukemia at the ASCO Annual Meeting.</li>
<li>Shares of Microbot Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBOT#NASDAQ">MBOT</a>) got a boost, surging 46% to $1.4601 after the company received FDA approval to proceed with its pivotal human clinical trial.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) shares were also up, gaining 35% to $31.17 after Roaring Kitty on a Reddit post, shared his position on the stock.</li>
</ul>
Equities Trading DOWN
<ul>
<li>CalAmp Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) shares dropped 60% to $1.0650 after the company announced it entered into a restructuring support agreement to take the company private and has voluntarily initiated proceedings under Chapter 11 of the United States Bankruptcy Code.</li>
<li>Shares of Lattice Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) were down 15% to $62.84 after the company announced an interim CEO following Jim Anderson&#8217;s decision to step down as President, CEO and Board member to pursue an opportunity with another company.</li>
<li>CNS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) was down, falling 38% to $0.1350. CNS Pharmaceuticals announced a 1-for-50 reverse stock split.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/news/24/06/39135431/top-3-utilities-stocks-that-may-plunge-in-q2">Top 3 Utilities Stocks That May Plunge In Q2</a> 
Commodities In commodity news, oil traded down 3.6% to $74.21 while gold traded up 0.9% at $2,367.80.
Silver traded up 1% to $30.745 on Monday, while copper rose 1.3% to $4.6625.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.32%, Germany's DAX rose 0.60% and France's CAC 40 gained 0.06%. Spain's IBEX 35 Index climbed 0.66%, while London's FTSE 100 fell 0.15%.
The HCOB Eurozone manufacturing PMI climbed to 47.3 in May compared to 45.7 in April, while German manufacturing PMI rose to 45.4 in May from 42.5 in April. The S&amp;P Global France manufacturing PMI rose to 46.4 in compared to 45.3 in April, while UK manufacturing PMI gained to 51.2 from 49.1.
Asia Pacific Markets
Asian markets closed mostly higher on Monday, with Japan's Nikkei gaining 1.13%, China's Composite Index falling 0.27%, Hong Kong's Hang Seng Index climbing 1.79% and India's S&amp;P BSE Sensex jumping 3.39%.
The HSBC India Manufacturing PMI fell to 57.5 in May from 58.8 in the prior month, while Caixin China general manufacturing PMI gained to 51.7 in May from 51.4 a month ago. The au Jibun Bank Japan manufacturing PMI rose to 50.4 in May from 49.6 in the earlier month.
Economics
<ul>
<li>The S&amp;P Global manufacturing PMI rose to 51.3 from prior reading of 50. However, analysts were expecting a reading of 50.9.</li>
<li>U.S. construction spending declined by 0.1% month-over-month to an annual rate of $2,099 billion in April compared to a 0.2% decline in the previous month and versus market estimates of a 0.2% increase.</li>
<li>The ISM manufacturing PMI fell to 48.7 in May versus 49.2 in April, and market expectations of of 49.6.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/06/39135201/how-to-earn-500-a-month-from-hewlett-packard-enterprise-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Hewlett Packard Enterprise Stock Ahead Of Q2 Earnings </a>

Eurozone

Commodities

Intraday Update

Markets

CAMP

CNSP

LSCC

MBOT

SAIC

Dow Dips Over 300 Points; GameStop Shares Spike Higher

Bio-Path Holdings (BPTH) has issued an announcement. Bio-Path Holdings, Inc. recently announced their presentation of promising data from a Phase 2...

Bio-Path Holdings Unveils Positive Leukemia Study Results

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Bio-Path (NASDAQ:<a href="https://investorplace.com/stock-quotes/bpth-stock-quote/">BPTH</a>) stock is rising higher on Friday alongside data from the oncology-focused company&rsquo;s <a href="https://finance.yahoo.com/news/bio-path-holdings-presents-data-110000607.html">Phase 2 clinical trial</a> of prexigebersen.



Prexigebersen&nbsp;is Bio-Path product candidate for the targeted treatment of acute myeloid leukemia (AML) alongside decitabine and venetoclax. The big news is the company presenting interim data from this study.



Bio-Path says that its ongoing trial continues to show tolerance for the drug with few adverse events. The company is also starting to see compelling efficiency data in AML patients.



Bio-Path CEO Peter Nielsen said the following about this news in a press release.




&ldquo;Given that our study is being conducted in the U.S., this encore presentation is an important step towards educating global oncology leaders on the benefits of prexigebersen and its potential to be another tool in their fight against AML.&rdquo;




<h2>BPTH Stock Movement Today</h2>



BPTH stock is experiencing heavy trading on Friday alongside this news. That has more than 4.3 million shares of the stock changing hands. This is well above its daily average trading volume of about 2.4 million shares.



BPTH stock is up 19.5% as of Friday morning.



Investors will want to keep reading for more of the most recent stock market news today!



We have all of the latest stock market stories investors need to know about on Friday! That includes everything happening with shares of Srivaru&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/svmh-stock-quote/">SVMH</a>), GameStop&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/gme-stock-quote/">GME</a>) and Arm&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/arm-stock-quote/">ARM</a>) stock this morning. All of this info is ready to go at the links below!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/06/why-is-srivaru-svmh-stock-up-122-today/">Why Is Srivaru (SVMH) Stock Up 122% Today?</a></li>



<li><a href="https://investorplace.com/2024/06/gme-stock-alert-roaring-kitty-appears-to-have-exited-all-gamestop-call-options/">GME Stock Alert: Roaring Kitty Appears to Have Exited All GameStop Call Options</a></li>



<li><a href="https://investorplace.com/2024/06/dear-arm-stock-fans-mark-your-calendars-for-june-24th/">Dear ARM Stock Fans, Mark Your Calendars for June 24</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/why-is-bio-path-bpth-stock-up-20-today/">Why Is Bio-Path (BPTH) Stock Up 20% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Bio-Path (BPTH) Stock Up 20% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Hasbro (NASDAQ:<a href="https://investorplace.com/stock-quotes/has-stock-quote/">HAS</a>) stock could be poised for further gains if Bank of America analysts are right about the toy and game company&rsquo;s shares.



Bank of America analysts <a href="https://www.investing.com/news/stock-market-news/bofa-upgrades-hasbro-stock-sees-a-50-upside-432SI-3484895">increased their price</a> target for HAS stock from $70 per share to $80 per share today. That&rsquo;s a potential 38% increase compared to the stock&rsquo;s prior closing price. It&rsquo;s also well above the analysts&rsquo; consensus estimate of $69 per share for the stock.



In addition to this, the Bank of America analysts also upgraded HAS stock from a &ldquo;neutral&rdquo; rating to a &ldquo;buy&rdquo; rating today. That roughly matches the <a href="https://www.marketbeat.com/stocks/NASDAQ/HAS/forecast/">analysts&rsquo; consensus rating</a> for Hasbro based on 11 opinions.



<h2>What&rsquo;s Behind the Bull Stance on HAS Stock?</h2>



Here&rsquo;s what the Bank of America analysts had to say about Hasbro in a note to clients obtained by Investing.com.




&ldquo;We do not believe consensus forecasts are fully accounting for the success of HAS&rsquo; digital gaming strategy with Monopoly Go!&rdquo;




On top of that, the analysts continue to see stable performance from the company&rsquo;s traditional game business. All of this is set to give the company strong growth in 2025.



HAS stock is up 5.3% as of Friday morning.



Investors will want to keep reading for even more of the most recent stock market stories.



We have all of the hottest stock market news available on Friday! Among that is what has shares of Tempus AI&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/tem-stock-quote/">TEM</a>), Bio-Path&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/bpth-stock-quote/">BPTH</a>) and Srivaru&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/svmh-stock-quote/">SVMH</a>) stock moving today. All of this info is ready at the following links!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/06/tem-stock-ipo-7-things-to-know-as-tempus-ai-starts-trading-today/">TEM Stock IPO: 7 Things to Know as Tempus AI Starts Trading Today</a></li>



<li><a href="https://investorplace.com/2024/06/why-is-bio-path-bpth-stock-up-20-today/">Why Is Bio-Path (BPTH) Stock Up 20% Today?</a></li>



<li><a href="https://investorplace.com/2024/06/why-is-srivaru-svmh-stock-up-122-today/">Why Is Srivaru (SVMH) Stock Up 122% Today?</a></li>
</ul>On <a href="https://investorplace.com/stock-types/penny-stocks/">Penny Stocks</a> and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/why-bank-of-america-thinks-hasbro-has-stock-can-gain-40-from-here/">Why Bank of America Thinks Hasbro (HAS) Stock Can Gain 40% From Here</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Bank of America Thinks Hasbro (HAS) Stock Can Gain 40% From Here

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Onsemi (NASDAQ:<a href="https://investorplace.com/stock-quotes/on-stock-quote/">ON</a>) layoffs are a hot topic on Friday as the semiconductor company has announced <a href="https://www.reuters.com/technology/semiconductor-cut-1000-jobs-globally-2024-06-13/">plans to cut 1,000 jobs</a>.



A statement from Onsemi notes that these cuts will be global as it looks to reduce costs and streamline operations. This also has it closing down several sites, <a href="https://www.newscentermaine.com/article/money/business/onsemi-announces-closure-south-portland-site-layoffs/97-f8a02b03-2dc4-4bb5-a1bd-9133e85ae616">including its South Portland location</a>, while asking around 300 employees to relocate.



The reason for these changes is the slowing demand for electric vehicles (EVs). The company&rsquo;s chips are used in EV drive trains to assist drivers. Its customers already have a strong supply of chips, lessening the need to order more from Onsemi.



The company also notes that these layoffs will result in it suffering $65 million charges in 2024 and $80 million charges in 2025, reports Reuters.



<h2>Onsemi Joins Layoffs Trend</h2>



Onsemi is only the latest in a growing number of companies that have been cutting jobs. Continued factors weighing on businesses include increased inflation and heightened interest rates.



Investors have been hoping for cuts to interest rates from the Federal Reserve. However, inflation has cooled enough for the regulator to consider any rate cuts right now.



ON stock is down 4.3% as of Friday morning and is down 11.9% year-to-date.



Investors will want to keep reading for more of the latest stock market stories!



We have all of the latest stock market news traders need to know about on Friday! A few examples include what&rsquo;s going on with shares of Hasbro&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/has-stock-quote/">HAS</a>), Tempus AI&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/tem-stock-quote/">TEM</a>) and Bio-Path&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/bpth-stock-quote/">BPTH</a>) stock&nbsp;today. All of this news is ready at the links below!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/06/why-bank-of-america-thinks-hasbro-has-stock-can-gain-40-from-here/">Why Bank of America Thinks Hasbro (HAS) Stock Can Gain 40% From Here</a></li>



<li><a href="https://investorplace.com/2024/06/tem-stock-ipo-7-things-to-know-as-tempus-ai-starts-trading-today/">TEM Stock IPO: 7 Things to Know as Tempus AI Starts Trading Today</a></li>



<li><a href="https://investorplace.com/2024/06/why-is-bio-path-bpth-stock-up-20-today/">Why Is Bio-Path (BPTH) Stock Up 20% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/onsemi-layoffs-2024-what-to-know-as-onsemi-cuts-1000-jobs/">Onsemi Layoffs 2024: What to Know as Onsemi Cuts 1,000 Jobs</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Onsemi Layoffs 2024: What to Know as Onsemi Cuts 1,000 Jobs

In a report released today, Jonathan Aschoff from Roth MKM maintained a Buy rating on Bio-Path Holdings (BPTH – Research Report), with a price targ...

Roth MKM Sticks to Their Buy Rating for Bio-Path Holdings (BPTH)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Tuesday!



Moving stocks are a new partnership, earnings, an acquisition deal and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>NLS Pharmaceutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/nlsp-stock-quote/">NLSP</a>) stock is rocketing more than 156% alongside heavy pre-market trading.</li>



<li>Actelis Networks (NASDAQ:<a href="https://investorplace.com/stock-quotes/asns-stock-quote/">ASNS</a>) shares are soaring over 137% after <a href="https://finance.yahoo.com/news/actelis-partners-carahsoft-major-us-203000611.html">announcing a new partnership</a> with Carahsoft.</li>



<li>MicroAlgo (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlgo-stock-quote/">MLGO</a>) stock is surging more than 25% despite a lack of news this morning.</li>



<li>Silk Road Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/silk-stock-quote/">SILK</a>) shares are increasing over 23% <a href="https://www.nasdaq.com/press-release/boston-scientific-announces-agreement-acquire-silk-road-medical-inc-2024-06-18">on an acquisition agreement</a>.</li>



<li>Mustang Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/mbio-stock-quote/">MBIO</a>) stock is gaining more than 22% as it <a href="https://investorplace.com/2024/06/why-is-mustang-bio-mbio-stock-up-347-today/">continues a clinical study rally</a>.</li>



<li>Fly-E Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/flye-stock-quote/">FLYE</a>) shares are rising over 21% after <a href="https://finance.yahoo.com/news/fly-e-group-inc-announces-191000159.html">going public earlier this month</a>.</li>



<li>Sonoma Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/snoa-stock-quote/">SNOA</a>) stock is heading more than 21% higher alongside its <a href="https://www.nasdaq.com/press-release/sonoma-pharmaceuticals-reports-fiscal-year-and-fourth-quarter-2024-financial-results">Q4 earnings report</a>.</li>



<li>Clene (NASDAQ:<a href="https://investorplace.com/stock-quotes/clnn-stock-quote/">CLNN</a>) shares are climbing over 18% higher on <a href="https://www.nasdaq.com/press-release/clene-presents-extended-survival-data-through-35-years-and-new-nfl-responder-results">extended survival data</a>.</li>



<li>Chegg (NYSE:<a href="https://investorplace.com/stock-quotes/chgg-stock-quote/">CHGG</a>) stock is jumping 18% on <a href="https://finance.yahoo.com/news/chegg-announces-restructuring-plan-vision-203500268.html">job cuts and a restructuring plan</a>.</li>



<li>BioLine Rx (NASDAQ:<a href="https://investorplace.com/stock-quotes/blrx-stock-quote/">BLRX</a>) shares are up more than 17% without any clear news this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Aerwins Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/awin-stock-quote/">AWIN</a>) stock is crashing over 52% as its <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318398965&amp;type=PDF&amp;symbol=AWIN&amp;cdn=c72eb168f714d139854f27235d706f2c&amp;companyName=AERWINS+Technologies+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-17">shares will be delisted today</a>.</li>



<li>Quantum (NASDAQ:<a href="https://investorplace.com/stock-quotes/qmco-stock-quote/">QMCO</a>) shares are plummeting more than 41% with the release of its <a href="https://www.nasdaq.com/press-release/quantum-reports-fiscal-full-year-2024-financial-results-2024-06-17">latest earnings report</a>.</li>



<li>Biolase (NASDAQ:<a href="https://investorplace.com/stock-quotes/biol-stock-quote/">BIOL</a>) stock is diving over 39% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318400377&amp;type=PDF&amp;symbol=BIOL&amp;cdn=37ce2e9246b65a79c01aa57fdd1c4b39&amp;companyName=Biolase+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-18">on a delisting notice</a>.</li>



<li>Connexa Sports Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/yyai-stock-quote/">YYAI</a>) shares are tumbling more than 23% on plans for a <a href="https://www.nasdaq.com/press-release/connexa-applies-imminent-1-20-reverse-split-remedy-bid-price-delisting-notice-2024-06">reverse stock split to avoid delisting</a>.</li>



<li>Interactive Strength (NASDAQ:<a href="https://investorplace.com/stock-quotes/trnr-stock-quote/">TRNR</a>) stock is taking an over 22% beating <a href="https://investorplace.com/2024/06/interactive-strength-trnr-stock-surges-129-after-reverse-stock-split/">after rallying yesterday</a>.</li>



<li>Srivaru (NASDAQ:<a href="https://investorplace.com/stock-quotes/svmh-stock-quote/">SVMH</a>) shares are sliding more than 15% as it <a href="https://investorplace.com/2024/06/why-is-srivaru-svmh-stock-up-122-today/">retreats from a recent rally</a>.</li>



<li>Virpax Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/vrpx-stock-quote/">VRPX</a>) stock is dropping over 15% on Tuesday morning.</li>



<li>Bio-Path (NASDAQ:<a href="https://investorplace.com/stock-quotes/bpth-stock-quote/">BPTH</a>) shares are decreasing more than 14% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318397757&amp;type=PDF&amp;symbol=BPTH&amp;cdn=71f3deb6bebaba5ab0528b1ade5a312b&amp;companyName=Bio-Path+Holdings+Inc.&amp;formType=424B3&amp;formDescription=Prospectus+%5BRule+424%28b%29%283%29%5D&amp;dateFiled=2024-06-17">secondary stock offering</a>.</li>



<li>Anitra (NYSEMKT:<a href="https://investorplace.com/stock-quotes/aztr-stock-quote/">AZTR</a>) stock is falling over 14% today.</li>



<li>Kineta (NASDAQ:<a href="https://investorplace.com/stock-quotes/ka-stock-quote/">KA</a>) shares close out our pre-market stock movers down more than 12% this morning.</li>
</ol><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-june-18th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Here's the major earnings before the open tomorrow

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Bio-Path Holdings (NASDAQ:<a href="https://investorplace.com/stock-quotes/bpth-stock-quote/">BPTH</a>) just reported results for the second quarter of 2024.<ul><li>Bio-Path Holdings reported earnings per share of -$1.16. This was above the analyst estimate for EPS of -$1.54.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/bpth-stock-earnings-bio-path-holdings-for-q2-of-2024/">BPTH Stock Earnings: Bio-Path Holdings Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BPTH Stock Earnings: Bio-Path Holdings Beats EPS for Q2 2024

Bio-Path GAAP EPS of -$1.16

Bio-Path Holdings, Inc. (BPTH) Q2 2024 Earnings Call Transcript

ADYEY

ASNS

AWIN

AZTR

BABA

BIOL

BLRX

CBWTF

CHGG

CLNN

FLYE

GLNG

GRAB

GRYP

ITMPF

LFWD

LNVGY

LYTS

MBIO

MLGO

NICE

NLSP

QMCO

SILK

SNOA

SPCB

SPTN

SVMH

TRMD

TRNR

VNRX

VRPX

YYAI

Financing

Press Releases

Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress

Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase

Bio-Path Holdings Provides Clinical Update and Expansion Plans

Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024

Bio-Path Holdings Reports Second Quarter 2024 Financial Results

Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A's Compelling Potential as Treatment for Advanced Solid Tumors

Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference

Comments

Bio-Path Hldgs

Noticias

Últimas noticias sobre Bio-Path Hldgs (NASDAQ:BPTH) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL